Literature DB >> 34411980

Structural optimization, synthesis and in vitro synergistic anticancer activities of combinations of new N3-substituted dihydropyrimidine calcium channel blockers with cisplatin and etoposide.

Marwa H El-Wakil1, Mohamed Teleb2, Marwa M Abu-Serie3, Sun Huang4, Gerald W Zamponi4, Hesham Fahmy5.   

Abstract

T-type calcium channels are considered potential drug targets to combat cancer. Combining T-type calcium channel blockers with conventional chemotherapy drugs represents a promising strategy towards successful cancer treatment. From this perspective, we report in this study the design and synthesis of a novel series of N3-sustituted dihydropyrimidines (DHPMs) as anticancer adjuvants to cisplatin (Cis) and etoposide (Eto). Full spectral characterization of the new compounds was done using FT-IR, 1H NMR, 13C NMR, and HRMS. Structure elucidation was confirmed by 2D NMR 1H-H COSY, HSQC and NOESY experiments. Novel derivatives were tested for their Ca2+ channel blocking activity by employing the whole cell patch-clamp technique. Results demonstrated that most compounds were potential T-type calcium channel blockers with the triazole-based C12 and C13 being the most selective agents against CaV3.2 channel. Further electrophysiological studies demonstrated that C12 and C13 inhibited CaV3.2 currents with respective affinity of 2.26 and 1.27 µM, and induced 5 mV hyperpolarizing shifts in the half-inactivation potential. Subsequently, C12 and C13 were evaluated for their anticancer activities alone and in combination with Cis and Eto against A549 and MDA-MB 231 cancer cells. Interestingly, both compounds exhibited potential anticancer effects with IC50 values < 5 µM. Combination studies revealed that both compounds had synergistic effects (combination index CI < 1) on Cis and Eto through induction of apoptosis (p53 activation and up-regulation of BAX and p21 gene expression). Importantly, in silico physicochemical and ADMET assessment of both compounds revealed their potential drug-like properties with decreased risk of cardiac toxicity. Hence, C12 and C13 are promising anticancer adjuvants through inhibition of CaV3.2 T-type calcium channels, thereby serving as eminent leads for further modification.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADMET; Anticancer; Electrophysiology; N3-substituted DHPMs; Synergism; T-type Ca(2+) channel

Mesh:

Substances:

Year:  2021        PMID: 34411980     DOI: 10.1016/j.bioorg.2021.105262

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  3 in total

1.  T-type calcium channels as therapeutic targets for treating "giant" retinoblastoma cancer cells.

Authors:  Emilio Carbone
Journal:  Pflugers Arch       Date:  2021-09-07       Impact factor: 3.657

2.  Design, Synthesis, Pharmacodynamic and In Silico Pharmacokinetic Evaluation of Some Novel Biginelli-Derived Pyrimidines and Fused Pyrimidines as Calcium Channel Blockers.

Authors:  Ahmed M Farghaly; Ola H Rizk; Inas Darwish; Manal Hamza; Mezna Saleh Altowyan; Assem Barakat; Mohamed Teleb
Journal:  Molecules       Date:  2022-03-30       Impact factor: 4.411

Review 3.  T-Type Calcium Channels: A Mixed Blessing.

Authors:  Dario Melgari; Anthony Frosio; Serena Calamaio; Gaia A Marzi; Carlo Pappone; Ilaria Rivolta
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.